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ApoptosisPKCd and p63 are respectively reported to play important roles in cell apoptosis. But there is no
report on interaction between them in regulation of apoptosis. In the present study, we found that
PKCd can directly associate and up-regulate TA isoforms of p63 (TAp63) proteins via increasing their
stability. PKCd kinase activity and Thr157 site in TAp63 are crucial for this PKCd-induced accumula-
tion of TAp63. PKCd can also enhance TAp63-mediated transcription and cell apoptosis. Taken
together, our data indicate that PKCd phosphorylates TAp63 proteins at Thr157 to stabilize them
and promote cell apoptosis.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Protein kinase C (PKC) is a family of cytoplasmic lipid-dependent
serine/threonine protein kinases inmammals [1]. PKCd is a member
of novel PKC isoforms and widely present in various tissues such as
brain and epithelial tissue cells. It is reported that PKCd is Ca2+
independent but activated by diacylglycerol, and plays a key role
in regulation of cell cycle and apoptosis in many kinds of cells [2].
PKCd can take part in cell apoptosis through physical interaction
with other apoptotic regulators. Studies demonstrate that PKCd is
phosphorylated and activated by c-Abl under oxidative stress.
Activated PKCd in turn can activate c-Abl by phosphorylation
which makes mitochondria release cytochrome C and activates
caspase-3, consequently promoting cell apoptosis [3]. Other stud-
ies have found that PKCd could bind to caspase-3 directly and
phosphorylate it to promote cell apoptosis [4]. PKCd also directly
phosphorylates tumor suppressor protein p53 at Ser15 and
Ser46, resulting in p53 accumulation and cell death [5–7]. In the
apoptotic response of cells to DNA damage, PKCd is cleaved into
a kinase-active catalytic fragment (PKCdCF), which mediates phos-
phorylation and accumulation of the p53 homologue p73b [8].
P63 is a new member of the p53 gene family. Due to alternative
transcription starting sites, p63 gene encodes two classes ofprotein isotypes, TAp63 and DNp63. TAp63 isotypes have a full
N-terminal transactivation domain (TAD) each and up-regulate
lots of downstream target genes like p53, while DNp63 isoforms
only possess incomplete TADs at their N-termini and inhibit tran-
scriptional activity of p53, p73 and TAp63 [9–11]. Furthermore,
owing to the C-terminal splicing in different ways, either type of
p63 has been subdivided into at least three different subtypes: a,
b, c (TAp63a, b, c and DNp63a, b, c) [12]. In recent years, studies
have shown that, TAp63 proteins play a key role in multiple apop-
tosis signaling pathways, and thus participate in apoptosis, despite
their very low abundance in somatic cells. Bax, p21, and other
downstream target genes can be activated by TAp63, causing cell
cycle arrest and apoptosis [12,13].
As TAp63 proteins play important roles in apoptosis, upstream
proteins of TAp63 are involved in apoptosis by interacting with
them. For example, Plk1 down-regulates TAp63a by phosphorylat-
ing it at Ser52, suppressing cell apoptosis [14]; TATA-binding
protein-like protein (TLP) and peptidyl-prolyl isomerase Pin1, can
promote cell apoptosis by up-regulating TAp63a [15,16]. It has been
reported that p53 and p73b are both up-regulated by PKCd, inducing
cell apoptosis [6–8]. Whether PKCd has effect on p63 is previously
unknown.Herewedemonstrate that PKCd stabilizes TAp63proteins
likely via phosphorylating them at Thr157, resulting in enhanced
TAp63-mediated transactivation and cell apoptosis.
2. Materials and methods
2.1. Cell culture and drug treatment
HeLa, H1299 and HCT116(p53/) cells were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM, Hyclone) with 10%
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penicillin G/streptomycin (Hyclone) at 37 C in a humidiﬁed 5%
CO2 incubator. For activation or inhibition of PKCd, 200 nM
Phorbol 12-myristate 13-acetate (PMA, Sigma) or 5 lM rottlerin
(Sigma) was supplemented 24 h post-transfection and was incu-
bated for 24 more hours.
2.2. Transfection
Cells were transfected with pcDNA-c-Myc-TAp63a, pcDNA-c-
Myc-TAp63c, pcDNA-c-Myc-DNp63a, pcDNA-c-Myc-DNp63c,
pKV-PKCd or pGFP-PKCd plasmid using LipofectAMINE 2000
(Invitrogen). Supplement of 50 ng GFP plasmid pEGFP-N1 was used
for each transfection, as a transfection efﬁciency control. To
knockdown PKCd, HeLA cells were transfected with siRNA directed
against PKCd or scramble control (Gene Pharma) using
LipofectAMINE 2000. After 48 h, cells were harvested for analysis.
2.3. Immunoprecipitation (IP)
Cells were lysed in IP lysis buffer [20 mM Tris–HCl (pH 7.9),
150 mM NaCl, 0.5% Nonidet P-40, 10 mM KCl, 0.5 m MEDTA, 10%
glycerol, 1.5 mMMgCl2]. Cell lysates containing 500 g total protein
were pre-cleared with normal mouse IgG (Santa Cruz) and protein
G-sepharose (GE health) for 1 h. Then the supernatant was incu-
bated with anti-c-Myc or anti-GFP or normal mouse IgG (Santa
Cruz) for 2 h and precipitated with protein G-Sepharose for 2 more
hours. The precipitates were washed with lysis buffer three times
at 4 C, resuspended in 30 lL of 2 SDS sample buffer and heated
at 100 C for 10 min, followed by immunoblot (IB) analysis.
2.4. Immunoblot (IB)
Cells were collected, washed with phosphate-buffered saline,
and resuspended in lysis buffer [20 mM Tris–HCl, pH 7.5,
150 mM NaCl, 1% Triton X-100, 10 mM MgCl2, 1 mM
phenylmethylsul-fonyl ﬂuoride (PMSF), 1 lg/mL leupeptin,
1 lg/mL pepstatin, 2 lg/mL aprotinin, 10 mM NaF, 1 mM EDTA,
and 1 mM Na3VO4]. Protein concentration was determined using
the Bio-Rad protein assay reagent (Bio-Rad). An equal amount of
protein was loaded into every well and separated on a 10% SDS–
PAGE, then transferred to polyvinylidene diﬂuoride membrane
(Bio-Rad), and hybridized to an appropriate primary antibody
and horseradish peroxidase-conjugated secondary antibody for
subsequent detection with ECL (Millipore). Immunoblot analysis
was performed with anti-p63 (Santa Cruz Biotechnology),
anti-pho-PKCd (Cell Signaling Technology), anti-PKCd (Santa Cruz
Biotechnology), anti-GFP (Santa Cruz Biotechnology), anti-b-actin
(Santa Cruz Biotechnology) or anti-PARP (Zenable bioscience).
Densitometric analysis was performed with Image Lab software
(Bio-Rad).
2.5. Site-directed mutagenesis
S147A, T157A, S319A and TS349, 350AA mutant TAp63a
plasmids were generated with the site-directed mutagenesis kit
(Stratagene), using pcDNA-c-Myc- TAp63a as a template.
2.6. Protein stability assay
To test protein stability of TAp63a, HeLa cells were
co-transfected with TAp63a and GFP plasmids plus PKCd or empty
vector. 24 h post-transfection, cells were supplemented with
50 lg/mL cycloheximide (CHX, Sigma) to block the biosynthesis
of nascent proteins. Then cells were cultured for additionalindicated durations to harvest. Cell lysates were used for immuno-
blot analysis. Cells were collected at the indicated time points for
IB analysis. b-actin was used as a loading control and GFP as a
transfection efﬁciency control.2.7. Luciferase assays
H1299 cells were transfected with a mixture of Bax-Luc and
pRL-TK-Renilla. Cells were harvested at 36 h after transfection
and lysed in Passive Lysis Buffer (Promega). Lysates were analyzed
for ﬁreﬂy and Renilla luciferase activities using the Dual Luciferase
Reagent Assay Kit (Promega).2.8. Flow cytometry analysis (FACS)
Cells were ﬁxed in 70% ethanol at 4 C overnight and stained
with 50 lg/mL propidium iodide (Sigma), supplemented with
80 lg/mL RNase A (Sigma) for 40 min at 37 C in the dark. Then,
cells were subjected to FACS analysis with FACScan ﬂow cytometer
(Becton Dickson). Data were analyzed using the Cell Quest
program.3. Results
3.1. PKCd can associate and up-regulate TAp63
It has been reported that PKCd can mediate phosphorylation of
the tumor suppressors p53 and p73b, increasing their protein
levels in cells [5–8]. Since p63 proteins are homologues of p53
and p73b, we wondered if PKCd has similar effects on p63 isoforms.
To this end, we co-transfected HeLa cells, which are deﬁcient in
p63 proteins, with PKCd and different TA or DN isoforms of p63
plasmids, respectively, using GFP plasmid as a transfection efﬁ-
ciency control. Cell lysates were subjected to immunoblot analysis.
The results showed that, TAp63a and TAp63cwere up-regulated in
the case of overexpression of PKCd, but the two isoforms of DNp63
were not affected (Fig. 1A). This suggests that PKCd can induce an
accumulation of TAp63 proteins in cells.
To extend these ﬁndings, rottlerin, which is a PKCd chemical
inhibitor [17], was used to treat the HeLa cells which were trans-
fected with TAp63a plus PKCd or vector control. Our data demon-
strate that PKCd-mediated TAp63a up-regulation was abrogated
by rottlerin (Fig. 1B). On the other hand, activation of endogenous
PKCd with its potent activator, phorbol 12-myristate 13-acetate
(PMA) [18], can signiﬁcantly increase protein level of transfected
TAp63a in HeLa cells, while simultaneous supplement of rottlerin
can obviously impair this effect (Fig. 1C). Further study demon-
strates that siRNA-mediated speciﬁc knock-down of endogenous
PKCd can also signiﬁcantly abrogate PMA-induced TAp63a accu-
mulation (Fig. 1D). These data suggest that PKCd up-regulates
TAp63 due to its kinase activity.
To examine whether PKCd directly interacts with TAp63, HeLa
cells were transfected with c-Myc-tagged TAp63a and
GFP-tagged PKCd plasmids. The cell lysates were subjected to
immunoprecipitation (IP) with anti-C-myc. Immunoblot (IB) anal-
ysis demonstrated that the precipitate contains both TAp63a and
PKCd (Fig. 1E). To ensure this ﬁnding, anti-GFP was used to precip-
itate PKCd. The results conﬁrmed that TAp63a can be coimmuno-
precipitated with PKCd (Fig. 1F). On the other hand, we failed to
detect physical interaction between PKCd and DNp63a with
co-immunoprecipitation assay (data not shown).
In a summary, these results suggest that PKCd physically inter-
acts with TAp63 and induces accumulation of TAp63 proteins in
cells due to the kinase activity of PKCd.
Fig. 1. PKCd directly associates and up-regulates TAp63. (A) Co-transfection of PKCd increases protein accumulation of TA but not DN isoforms of p63. Different isoforms of
p63, including TAp63a, DNp63a, TAp63c, and DNp63c were respectively co-transfected with PKCd (indicated as +) or its vector control (indicated as ) into Hela cells, using
GFP as a transfection efﬁciency control. 24 h post-transfection, cells were harvested and subjected to IB analysis with indicated antibodies. (B) PKCd inhibitor rottlerin
abrogates PKCd-induced TAp63a accumulation. HeLa cells transfected with TAp63a and GFP plus PKCd (indicated as +) or its vector control (indicated as ) were treated
without (left 2 lanes) or with rottlerin (right 2 lanes). (C) Activation of endogenous PKCdwith PMA induces accumulation of TAp63a which can be reversed by rottlerin. HeLa
cells transfected with TAp63a and GFP were treated with indicated drugs. (D) Knockdown of endogenous PKCd abrogates PMA-induced accumulation of TAp63a. HeLa cells
transfected with TAp63a and GFP were simultaneously transfected with PKCd siRNA or scramble control, or treated with PMA. (E) and (F) PKCd directly associates TAp63a.
HeLa cells were co-transfected with c-Myc-TAp63a and GFP-PKCd. Whole-cell lysates were subjected to immunoprecipitation (IP) with normal mouse IgG, monoclonal
anti-c-Myc antibody or monoclonal anti-GFP antibody. IP products were subjected to immunoblot (IB) analysis with indicated antibodies.
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TAp63
It is reported that PKCd can phosphorylate p53 and p73 to
stabilize them [7,8]. To examine whether PKCd-induced TAp63
accumulation is via enhancing its protein stability, we measured
half-life of TAp63a protein in the presence or absence of
transfected PKCd. The results showed that the half life of TAp63a
was prolonged from about 30 min to more than 120 min by
co-transfection of PKCd (Fig. 2A and B). On the other hand, quanti-
tative PCR analysis revealed that mRNA levels of TAp63 were not
affected by PKCd (data not shown). These results demonstrate that
PKCd can increase the stability of TAp63a protein in the cells,
leading to accumulation of TAp63a.
3.3. Thr157 is critical for PKCd-mediated accumulation of TAp63
Since we found that PKCd directly binds to TAp63 and induces
the latter’s accumulation through its kinase activity, we wondered
which phosphorylation site of TAp63 is critical to this stability reg-
ulation. To identify this site, we constructed several point muta-
tions of TAp63a, including S146A, T157A, S319A and TS349,
350AA, to prevent phosphorylation of these putative PKCd modiﬁ-
cation sites. These four mutants and wild-type TAp63a were
respectively co-transfected with PKCd or its vector control in
HeLa cells. 24 h post-transfection, cells were harvested and sub-
jected to immunoblot analysis. The results demonstrate that
T157A, but not other point mutations, can signiﬁcantly abrogate
PKCd-induced accumulation of TAp63a in cells (Fig. 3A and B).
This suggests that phosphorylation of Thr157 mediated by PKCd
is crucial to stabilize TAp63.
3.4. PKCd up-regulates TAp63-mediated transactivation and cell
apoptosis
As homologues of p53, TAp63 proteins function as transcription
factors, with lots of target genes, such as p21 and Bax [12,13]. Toinvestigate whether PKCd-mediated up-regulation of TAp63a can
stimulate transcription of its target genes, luciferase reporter
assays were performed with H1299 cells, which are deﬁcient in
either p63 or p53. Our results demonstrated that TAp63a increased
the Bax-luc reporter activity, which was further enhanced by PKCd
(Fig. 4A). In addition, PKCd activator PMA also signiﬁcantly
increased transactivity of TAp63a, while PKCd inhibitor rottlerin
impaired PKCd-mediated up-regulation of TAp63a transactivity
(Fig. 4B). According to our data not shown, TAp63a mediated
expression of p21-luc reporter can also be up-regulated by PKCd.
These results suggest that PKCd has a positive role in regulating
expression of downstream target genes of TAp63a.
TAp63a is a well-known tumor suppressor which can induce
cell apoptosis via up-regulating its downstream target genes
[12]. To determine whether PKCd affects TAp63 function in cell
apoptosis, HCT116(p53/) cells, which is another cell line deﬁ-
cient in either p63 or p53, were used to overexpress PKCd and
TAp63a. 24 h post-transfection, cells were harvested and subjected
to IB and FACS analysis. The results demonstrated that
TAp63a-induced PARP cleavage, which is a molecular marker of
cell apoptosis, was further increased by PKCd overexpression
(Fig. 4C). On the other hand, FACS analysis showed that TAp63a
increased the percentage of cells in subG1 phase, while simultane-
ous overexpression of PKCd signiﬁcantly enhanced this
TAp63a-induced subG1 arrest (Fig. 4D). These data suggest that
PKCd promotes TAp63a-induced cell apoptosis.4. Discussion
As a Ser/Thr protein kinase, PKCd has been reported to phospho-
rylate several proteins, including c-Abl, AP21, Caspase-3, p53 and
p73b, to promote cell apoptosis [3–8,19]. In this study, we show
that TAp63, which are important homologues of p53 and p73b,
can be up-regulated by PKCd, resulting in elevated cell apoptosis.
We found that PKCd can directly bind to TAp63 proteins and induce
their accumulation in cells via increasing their stability; this effect
Fig. 2. PKCd increases protein stability of TAp63a. (A) HeLa cells were transfected
with TAp63a and GFP plasmids plus PKCd plasmid or its vector control. 24 h post-
transfection, the cells were treated with cycloheximide (CHX) for indicated
durations followed by IB analysis. Protein levels of TAp63a were normalized with
b-actin, and the protein half-life was quantiﬁed. The value of 0-min was set as 1.0.
(B) The half-life of TAp63a protein was quantiﬁed from 3 independent experiments.
Data were presented as fold activation with standard deviation.
Fig. 3. T157A mutation abrogates PKCd-induced accumulation of TAp63a. (A) HeLa
cells were transfected with PKC plasmid or its vector control, together with GFP and
wild type (WT) or S146A/T157A/S319A/TS349, 350AA mutant TAp63. 24 h post-
transfection, cells were harvested and subjected to IB analysis. (B) Data from 3
independent experiments were quantiﬁed and presented as fold activation with
standard deviation. The relative level of wild type or each mutant TAp63a in the
absence of transfected PKC was respectively set as 1.0.
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mutation in TAp63a; PKCd-mediated up-regulation of TAp63 can
enhance transcription of its downstream target genes and further
induce cell apoptosis.
Multiple p63 isoforms are encoded by the p53-related p63 gene.
Due to their key roles in a variety of essential biological processes,
abundances of p63 proteins are tightly controlled. Protein stability
is a major factor affecting protein abundance in cells. Accumulating
reports demonstrate that TAp63 proteins are much less stable than
DNp63 [16,20]. In response to some extrinsic stress, DNp63 pro-
teins undergo degradation, while TA isoforms of p63 become more
stable and accumulate in cells, so as to trigger cell apoptosis [21].
Up to now, it is not well understood how p63 protein stability is
regulated. According to our previous study, as well as reports from
other groups, phosporylation at multiple sites of p63 proteins can
affect their stability. For instance, kinases ATM, CDK2, p70S6K, Plk,
p38, HIPK2 and GSK3 were reported to phosphorylate different p63
isoforms and promote their degradation [14,22–25]; c-Abl medi-
ates phosphorylation of Y149, Y171, and Y289 of TAp63 proteins
to make them more stable [26], while it also phosphorylates Y55,
Y137, and Y308 of DNp63a to destabilize it [27]; the kinase IKKb
stabilizes TAp63c but destabilizes DNp63a [28,29]. Recently, we
found that phosphorylation of Thr538 in TAp63a as well as thecorresponding site in DNp63a mediated by an unknown kinase
may lead to Pin1-mediated isomerization of the adjacent PY motif,
consequently preventing them from proteasomal degradation
mediated by WWP1 E3 ligase [16]. In the present study, we found
that kinase activity of PKCd is essential for its effect on TAp63 pro-
tein accumulation. This suggests that PKCd stabilizes TAp63 pro-
teins via phosphorylating them. Compared with DNp63 isoforms,
TAp63 proteins possess intact TADs at their N-termini. Our data
suggest that PKCd can phosphorylate TAp63 at their Thr157 site
to increase their protein stability. Though this site is also included
in DNp63 proteins, our data demonstrate that they cannot be
stabilized by PKCd (Fig 1A). Further study shows that PKCd can
directly bind to TAp63a (Fig. 1E and F), but not DNp63a (data
not shown). This indicates that the intact TADs may be necessary
for PKCd-mediated phosphorylation of Thr157 in p63 proteins.
Further investigations are required to deﬁne the underlying
mechanism.
Endogenous TAp63 proteins are barely detectable in somatic
cells in general cases [30]. Ectopic expression or stress-induced
accumulation of TAp63 can promote cell cycle arrest and apoptotic
cell death through activating p53 pro-apoptotic targets, such as
Puma, Bax and p21 [13,26,31–33]. Our data demonstrate that
PKCd-induced accumulation of TAp63 may increase transcription
of Bax-luc reporter, and enhance cell apoptosis. This conclusion
is consistent with the evidence that PKCd can promote cell apopto-
sis through interaction with other proteins, such as c-Abl,
caspase-3, p53 and p73b [3–5,8]. It is previously reported that
PKCd promoter contains three p53-like binding sites, and TAp63a
can activate transcription of PKCd [34]. So there is likely a
Fig. 4. PKCd up-regulates TAp63a-mediated transactivation and cell apoptosis. (A) PKCd up-regulates TAp63a-mediated expression of Bax-Luc reporter. (B) Activation of
endogenous PKCd with PMA up-regulates TAp63a-mediated expression of Bax-Luc reporter, while rottlerin impairs PKCd-mediated up-regulation of TAp63a transactivity.
H1299 cells were transfected with indicated plasmids and (or) treated with indicated chemicals. Fireﬂy and Renilla luciferase activities were measured. The Bax-Luc activity
was normalized to Renilla activity and presented as fold activation with standard deviation (n = 3). (C) and (D) Overexpression of PKCd promotes TAp63-mediated apoptosis.
HCT116(p53/) cells were transfected with indicated plasmid plus GFP plasmid. 24 h post-transfection, cells were harvested and half of them were subject to IB analysis (C)
while another half were used for DNA content-based apoptotic cell analysis by FACS (D). PARP cleavage (C) or subG1 arrest (D) was used as an index of cell apoptosis.
2098 D. Li et al. / FEBS Letters 589 (2015) 2094–2099feedforward regulation of PKCd-TAp63 expression in cells: under
some circumstances, PKCd is activated and consequently stabilizes
TAp63 proteins; upregulated TAp63 can enhance transcription of
PKCd, which may further increase TAp63 protein levels to trigger
cell apoptosis and cell cycle arrest. In combination with recent evi-
dence supporting PKCd as a tumor suppressor [35], it is possible to
develop therapies for some cancer types via activating or restoring
PKC activity, using chemical PKC activators such as PMA.
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